Complete Up To Date Information about Baytril Antibacterial Injectable Solution.
NADA Number: 140-913 | |
| Proprietary Name |
Baytril® Antibacterial Injectable Solution |
|---|---|
| Sponsor |
Bayer Healthcare LLC, Animal Health Division |
| Sponsor Address |
P. O. Box 390 Sahwnee Mission, KS 66201 USA |
| Ingredients |
Enrofloxacin |
| Species |
Dog, no use class stated or implied |
| Routes of Administration |
Intramuscular |
| Dose Form |
Liquid (solution) |
| Drug Form |
Liquid (solution) |
| Dispensing Status |
RX |
| Patent Number |
4670444 |
| Exclusivity |
Granted for the treatment of the following infections in dogs: dermal infections (wounds and abscesses)
caused by susceptible strains of Escherichia coli, Klebsiella pneumoniae, Proteus mirabilis, and Staphylococcus aureus; respiratory infections (pneumonia, tonsillitis, rhinitis) caused by susceptible strains of Escherichia
coli and Staphylococcus aureus; urinary cystitis caused by susceptible
strains of Escherichia coli, Proteus mirabilis and Staphyloccus aureus.
The product is approved in liquid form in a concentration of 22.7 mg/ml and
is to be administered intramuscularly. |
|
Dosage Amount, Indications & Limitations |
522.812 Enrofloxacin solution. Specifications: Each milliliter of sterile aqueous solution contains 22.7 milligrams of enrofloxacin. Conditions of use: Dogs Amount: 2.5 milligrams intramuscularly per kilogram (1.13 milligrams per pound) of body weight as an initial dose only. Indications: Dogs for management of diseases associated with bacteria susceptible to enrofloxacin. Limitations: As a single, intramuscular, initial dose followed by use of tablets twice daily for 2 to 3 days beyond cessation of clinical signs to a maximum of 10 days. Federal law restricts this drug to use by or on the order of a licensed veterinarian. |
| Tolerances |
A tolerance of 0.1 part per million for desethylene ciprofloxacin (marker residue) has been established in liver (target tissue) of cattle . |